Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...
USA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) ...
Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...
Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...
Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...
Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition ...
Comparison measures of lung function and improved categorization of cardiovascular disease (CVD) risk were among the key ...
clinicaltrialsarena on MSN8d
MSD’s trial of drug for pulmonary arterial hypertension meets primary endpointMSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.
Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...
When frostbitten limbs warm up again, blood rushes back into the tissue. With that blood come compounds such as histamines ...
Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...
New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback